$1.93
+0.01 (+0.52%)
Open$1.93
Previous Close$1.92
Day High$2.02
Day Low$1.89
52W High$5.50
52W Low$1.54
Volume—
Avg Volume913.3K
Market Cap82.11M
P/E Ratio—
EPS$-1.70
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+649.2% upside
Current
$1.93
$1.93
Target
$14.46
$14.46
$8.98
$14.46 avg
$17.59
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 18.60M | 19.31M | 20.88M |
| Net Income | -5,133,777 | -5,587,628 | -4,631,912 |
| Profit Margin | -27.6% | -28.9% | -22.2% |
| EBITDA | -5,451,350 | -5,303,939 | -6,015,367 |
| Free Cash Flow | -4,165,501 | -4,081,500 | -5,685,079 |
| Rev Growth | +22.8% | -8.3% | +12.1% |
| Debt/Equity | 0.56 | 0.49 | 0.59 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $261.07 | +3.99% | 126.9 | 461.26B |
| AMGN | Amgen Inc | $374.15 | +3.55% | 25.9 | 201.93B |
| GILD | Gilead Sciences Inc | $131.27 | +4.21% | 17.7 | 162.98B |
| VRTX | Vertex Pharmaceuticals Inc | $528.04 | +6.03% | 30.4 | 131.79B |
| REGN | Regeneron Pharmaceuticals | $654.27 | +4.73% | 15.5 | 68.59B |
| ALNY | Alnylam Pharmaceuticals Inc | $312.78 | +3.68% | 72.4 | 41.76B |